万恶之源😒_老虎社区_美港股上老虎

万恶之源😒

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":402500995486048,"tweetId":"402500995486048","gmtCreate":1739285049927,"gmtModify":1739285051732,"author":{"id":3576724815704857,"idStr":"3576724815704857","authorId":3576724815704857,"authorIdStr":"3576724815704857","name":"去会所","avatar":"https://static.tigerbbs.com/de401c0bd93eac5813aa71ee994e439c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>万恶之源😒</p></body></html>","htmlText":"<html><head></head><body><p>万恶之源😒</p></body></html>","text":"万恶之源😒","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/402500995486048","repostId":2510822559,"repostType":2,"repost":{"id":"2510822559","kind":"news","pubTimestamp":1739254104,"share":"https://www.laohu8.com/m/news/2510822559?lang=&edition=full","pubTime":"2025-02-11 14:08","market":"hk","language":"zh","title":"强生(JNJ.US)埃万妥单抗联合疗法在华获批上市 用于肺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2510822559","media":"智通财经","summary":"智通财经APP获悉，2月11日，强生宣布埃万妥单抗注射液已获得中国国家药品监督管理局批准。根据强生新闻稿，此次埃万妥单抗的获批是基于一项随机、开放标签、PAPILLON临床3期研究结果。该研究表明，与单独化疗相比，埃万妥单抗联合化疗可将疾病进展或死亡风险降低61%。","content":"<html><body><p>智通财经APP获悉，2月11日，<a href=\"https://laohu8.com/S/JNJ\">强生</a>(JNJ.US)宣布埃万妥单抗注射液已获得中国国家药品监督管理局(NMPA)批准。埃万妥单抗(amivantamab)是一款<strong>EGFR/MET双特异性抗体疗法，本次获批用于与卡铂和培美曲塞联合给药，用于经检测确认携带表皮生长因子受体(EGFR)20号外显子插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。</strong></p><p>埃万妥单抗(英文商品名为Rybrevant)是强生旗下公司开发的一款靶向EGFR和MET的在研全人源化双特异性抗体，它除了能够阻断EGFR和MET介导的信号传导以外，还可以引导免疫细胞靶向携带激活性和抗性EGFR/MET突变和扩增的肿瘤。</p><p>在中国，<strong>埃万妥单抗曾于2020年被CDE纳入突破性治疗品种</strong>，用于治疗含铂双药化疗期间或之后进展，或对含铂化疗不耐受的<strong>EGFR 20号外显子插入突变的转移性或手术不可切除的NSCLC患者。</strong></p><p>根据强生新闻稿，此次埃万妥单抗的获批是基于一项随机、开放标签、PAPILLON临床3期研究结果。<strong>该研究表明，与单独化疗相比，埃万妥单抗联合化疗可将疾病进展或死亡风险降低61%。</strong></p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生(JNJ.US)埃万妥单抗联合疗法在华获批上市 用于肺癌一线治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生(JNJ.US)埃万妥单抗联合疗法在华获批上市 用于肺癌一线治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-11 14:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1248215.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2月11日，强生(JNJ.US)宣布埃万妥单抗注射液已获得中国国家药品监督管理局(NMPA)批准。埃万妥单抗(amivantamab)是一款EGFR/MET双特异性抗体疗法，本次获批用于与卡铂和培美曲塞联合给药，用于经检测确认携带表皮生长因子受体(EGFR)20号外显子插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。埃万妥单抗(英文商品名为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1248215.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4559":"巴菲特持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4581":"高盛持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4504":"桥水持仓","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","JNJ":"强生","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4532":"文艺复兴科技持仓","BK4592":"伊斯兰概念","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","BK4534":"瑞士信贷持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1248215.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2510822559","content_text":"智通财经APP获悉，2月11日，强生(JNJ.US)宣布埃万妥单抗注射液已获得中国国家药品监督管理局(NMPA)批准。埃万妥单抗(amivantamab)是一款EGFR/MET双特异性抗体疗法，本次获批用于与卡铂和培美曲塞联合给药，用于经检测确认携带表皮生长因子受体(EGFR)20号外显子插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。埃万妥单抗(英文商品名为Rybrevant)是强生旗下公司开发的一款靶向EGFR和MET的在研全人源化双特异性抗体，它除了能够阻断EGFR和MET介导的信号传导以外，还可以引导免疫细胞靶向携带激活性和抗性EGFR/MET突变和扩增的肿瘤。在中国，埃万妥单抗曾于2020年被CDE纳入突破性治疗品种，用于治疗含铂双药化疗期间或之后进展，或对含铂化疗不耐受的EGFR 20号外显子插入突变的转移性或手术不可切除的NSCLC患者。根据强生新闻稿，此次埃万妥单抗的获批是基于一项随机、开放标签、PAPILLON临床3期研究结果。该研究表明，与单独化疗相比，埃万妥单抗联合化疗可将疾病进展或死亡风险降低61%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/402500995486048"}